Tukysa Archives -

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance,

Seagen’s breast cancer drug Tukysa turned down by NICE

https://pharmaphorum.com/news/seagens-breast-cancer-drug-tukysa-turned-down-by-nice/

The FDA has approved Seattle Genetics’ breast cancer drug Tukysa (tucatinib) four months early, including in certain patients

Seattle Genetics snags early approval for advanced breast cancer drug

https://pharmaphorum.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug/

Tukysa